ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

PeopleandPicks.com is Zacks' Community Website
Find great stocks and great stock pickers in our online community. It's social, it's profitable and it's Free! Join the fun at PeopleandPicks.com

Quote:

Search for Ticker

Free Membership

Search:

CERS: Cerus Cp - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

CERUS CP (NASD)
CERS	1.97	0.02	(1.03%)	Vol. 78,013	12:28 ET

Cerus Corporation is developing medical products based on a platformtechnology that prevents nucleic acid replication. The company's initialapplication of this technology is the development of systems to inactivateviruses, bacteria and other pathogens in blood components used for transfusion. The company is also focusing research and development efforts on other potential health care applications for this platform technology, including pathogen inactivation of source plasma used for fractionation, improving the outcomes of stem cell transplantation.

General Information

CERUS CORP

2411 Stanwell Drive Concord, CA 94520 Phone: 925-288-6000 Fax: 925-603-9099 Web: www.cerus.com Email: ir@cerus.com

Industry	MED PRODUCTS
Sector:	Medical

Fiscal Year End	December
Last Reported Quarter	09/30/09
Next EPS Date	02/25/2010

Price and Volume Information

Zacks Rank
Yesterday's Close	1.95
52 Week High	3.57
52 Week Low	0.55
Beta	2.74
20 Day Moving Average	737,426.38
Target Price Consensus	4

% Price Change
4 Week	-2.01
12 Week	-1.02
YTD	178.57

% Price Change Relative to S&P 500
4 Week	-5.75
12 Week	-10.65
YTD	136.46

Share Information
Shares Outstanding (millions)	38.65
Market Capitalization (millions)	75.37
Short Ratio	3.91
Last Split Date	N/A

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	-0.09
Current Year EPS Consensus Estimate	-0.66
Estimated Long-Term EPS Growth Rate	-
Next EPS Report Date	02/25/2010

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	2.00
30 Days Ago	3.00
60 Days Ago	3.00
90 Days Ago	3.00

Fundamental Ratios

P/E
Current FY Estimate:	-
Trailing 12 Months:	-
PEG Ratio	-

EPS Growth
vs. Previous Year	40.74%
vs. Previous Quarter	15.79%

Sales Growth
vs. Previous Year	24.01%
vs. Previous Quarter:	14.46%

Price Ratios
Price/Book	4.62
Price/Cash Flow	-
Price / Sales	4.67

ROE
09/30/09	-142.23
06/30/09	-134.20
03/31/09	-112.90

ROA
09/30/09	-61.62
06/30/09	-65.66
03/31/09	-61.75

Current Ratio
09/30/09	2.25
06/30/09	2.33
03/31/09	2.93

Quick Ratio
09/30/09	1.76
06/30/09	1.57
03/31/09	1.98

Operating Margin
09/30/09	-156.66
06/30/09	-187.29
03/31/09	-208.65

Net Margin
09/30/09	-156.32
06/30/09	-186.82
03/31/09	-208.17

Pre-Tax Margin
09/30/09	-156.32
06/30/09	-186.82
03/31/09	-208.17

Book Value
09/30/09	0.42
06/30/09	0.37
03/31/09	0.55

Inventory Turnover
09/30/09	1.17
06/30/09	0.90
03/31/09	0.90

Debt-to-Equity
09/30/09	0.00
06/30/09	0.00
03/31/09	0.00

Debt to Capital
09/30/09	0.04
06/30/09	0.00
03/31/09	0.00


About Zacks \| Advertise \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2009 Zacks Investment Research